Washington, April 25 : Although the U. S. Food and Drug Administration have approved botulinum toxin A (“Botox”) injections for preventive treatment for chronic migraines, a review and analysis of previous studies have found only a small to modest benefit for patients with chronic migraine headaches and chronic daily headaches.
But botox injections were not associated with greater benefit than placebo for preventing episodic migraine or chronic tension-type headaches.
Botulinum toxin A injections were first proposed as headache treatment when it was observed that patients with chronic headaches receiving cosmetic botulinum injections experienced headache improvement, prompting several case series that suggested benefit.
However, the medical literature on botulinum effectiveness for headaches has been mixed.
Jeffrey L. Jackson, M. D., M. P. H., of the Medical College of Wisconsin, Milwaukee, and colleagues performed a review and meta-analysis to assess the association of botulinum toxin A with reducing headache frequency when used for preventive treatment of migraine, tension, or chronic daily headaches in adults.
For the study, headaches were categorized as episodic (less than 15 headaches per month) or chronic (15 or more headaches per month) migraine and episodic or chronic daily or tension headaches.
The researchers identified 27 randomized placebo-controlled trials that included 5,313 study participants and 4 randomized comparisons with other medications that met study inclusion criteria.
Pooled analyses of the data suggested that botulinum toxin A was associated with fewer headaches per month among patients with chronic daily headaches and among patients with chronic migraine headaches.
There was no significant association between use of botulinum toxin A and reduction in the number of episodic migraine or chronic tension-type headaches.
Compared with placebo, botulinum toxin A was associated with a greater frequency of blepharoptosis (drooping of the upper eyelid), skin tightness, paresthesias (a prickly, tingling sensation), neck stiffness, muscle weakness, and neck pain.
In the 4 trials that compared botulinum toxin A with other treatment modalities, botulinum toxin A was not associated with reduction in headache frequency compared with topiramate (1.4 headaches per month) or amitriptyline (2.1 headaches per month) for prophylaxis against chronic migraine headaches.
“Botulinum toxin A was not associated with a reduction in headache frequency vs. valproate in a study of patients with chronic and episodic migraines (0.84 headaches per month) or in a study of patients with episodic migraines
(0.3 headaches per month),” the researchers wrote.
“Botulinum toxin A was associated with a greater reduction in average headache severity than methylprednisolone in a single trial among patients experiencing chronic tension-type headaches (-2.5 headaches per month).
“Our analyses suggest that botulinum toxin A may be associated with improvement in the frequency of chronic migraine and chronic daily headaches, but not with improvement in the frequency of episodic migraine, chronic tension-type headaches, or episodic tension-type headaches.
“However, the association of botulinum toxin A with clinical benefit was small. Botulinum toxin A was associated with a reduction in the number of headaches per month from 19.5 to 17.2 for chronic migraine and from 17.5 to 15.4 for chronic daily headaches,” they added.
The finding was reported in the latest issue of JAMA. (ANI)